EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...

The company plans to launch the first version of its AI Advocate tool, aimed at helping patients manage and guide their overall healthcare, in the third quarter of this year.

A Medical University of South Carolina team reports in Frontiers in Immunology that it has engineered a new type of ...

Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Crucially, EVs shield their cargo from biofluid interference, providing a more accurate reflection of the pathophysiological state of their parental cells and serving as a reliable window for dynamic ...

Chronic traumatic encephalopathy, or CTE, is a brain disease linked to repeated hits to the head, often seen in military veterans and athletes.

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s potential. Click for more on ZBIO stock.